In the morning, the Hang Seng Health Care Index (HSHCI) rose more than 3 per cent. The pharmaceutical sector strengthened, with BeiGene, Ltd. and Kangfang Bio-B up more than 8%, Vivia Bio, INNOVENT BIO, Keji Pharmaceutical-B, Yao Ming Juenuo-B up more than 7%, Genscript Biotech Corporation, Fang Da Holdings, Xintong Medical-B, Rongchang Bio-B and other stocks rose one after another. Hang Seng Medical ETF (513060) opened up, up more than 2%, turnover of more than 200 million, active trading, strong momentum!

Wanhe Securities said that at present, the valuation of the pharmaceutical industry is historically low and has a lot of room for improvement. The overall valuation of the pharmaceutical industry is still at a historically low level, and the value of plate allocation is prominent.